Psychiatry

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.

Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.

The lead author of treatment recommendations weighs in on their current use and future research.

Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.

New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.

Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.

Linda Chokroverty, MD, discusses the significance of timing, communication and care coordination when children are affected by disasters or trauma.

APA president-elect Rebecca W. Brendel, MD, JD, discusses the need to prepare for a "twin mental health pandemic" while continuing to appropriately facilitate innovations in psychiatric care.

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.

A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.

It takes even more than a village to provide the comprehensive care needed for aging, neurocognitive patients, says Rajesh R. Tampi, MD, MS.

A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.

Rajesh R. Tampi, MD, MS, discusses the evolved definition of dementia as a cognitive disorder, and how its spectrum of symptoms impact clinical development.

Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.

The first controlled trial of the combination therapy shows its benefit in 6-week depressive symptom improvement versus lone bupropion.

Dr. Carolyn Rowley is leading the California Sickle Cell Disease Mental Health and Wellness Initiative to provide mental health services free to people living with sickle cell disease.

Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.

An expert panel shares insight on the future treatment landscape for treatment-resistant depression.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in treatment-resistant depression, as well as alternative payment models.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

Dr. Shirah Vollmer and Dr. Michael Ziffra host a Question & Answer Session addressing common inquiries about mental health treatment in the primary care setting.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.

David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.